首页> 外国专利> ADENOSINE ANALOGUES HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES

ADENOSINE ANALOGUES HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES

机译:腺苷类似物具有抗高血压,心脏保护作用,抗缺血和抗磷脂特性

摘要

1. A compound of the formula wherein: K - N, N - O, or CH; Q - CH2 or O; R6 is hydrogen, C1-10 alkyl, allyl, 2-methylallyl, 2-butenyl, or C3-10cycloalkyl; X is where the nitrogen of the ring of X is substituted by Y; E is O or S; Y is hydrogen, C1-20alkyl, C1-20alkyl, substituted with phenyl, C1-20alkyl, substituted with naphtyl, C1-20alkyl, substituted with substituted phenyl, C1-20alkyl, substituted with substituted naphtyl, 4-10 membered heterocyclic ring, comprising at least one atom N, O or S, substituted 4-10 membered heterocyclic ring, comprising at least one atom N, O, S, C1-20alkyl, substituted with 4-10 membered heterocyclic ring, comprising at least one atom N, O, S, or C1-20alkyl, substituted with substituted 4-10 membered heterocyclic ring, comprising at least one atom N, O, S; n and p are independently 0,1, 2, or 3, provided that n + p is at least 1; T is hydrogen, C1-20alkyl, C1-20acyl, C1-20thioacyl, halo, carboxyl, or R3O-CH2; R1, R2, and R3 are independently H, C1-20alkyl, C3-10cycloalkyl; A is hydrogen, C1-20alkyl, C1-20hydroxyalkyl, C1-20alkyl, substituted C1-20alkoxy, OR'; B is hydrogen, C1-20alkyl, C1-20hydroxyalkyl, C1-20alkyl, substituted C1-20alkoxy, or OR''; R' and R'' are independently hydrogen, C1-20alkyl, C1-20alkyl substituted with phenyl, C1-20alkyl substituted with naphtyl, carbamoyl, C1-20alkylcarbamoyl, di-(C1-20alkyl)-carbamoyl, acyl, C1-20alkoxycarbonyl, phenylC1-20aralkoxycarbonyl, naphtylC1-20aryloxycarbonyl, phenyloxycarbonyl, nathtyloxycarbonyl, or, when A and B are OR' and OR'', respectively, R' and R'' together may form H, ORc, wherein Rc - hydrogen, C1-20alkyl, wherein Rd and Re - are independently hydrogen, C1-20alkyl; together with the carbon atom to which they are attached may form a C3-101,1-cycloalkyl group; or a pharmaceutically acceptable salt thereof. 2. A compound according to Claim 1 wherein K is N; T is hydroxymethyl or methoxymethyl; A and B are hydroxy: X is and n + p is 3 or 4; or a pharmaceutically acceptable salt thereof. 3. A compound according to Claim 2 which is (2R,3R,4S,5R)-2-hydroxymethyl-5-[6-[1-(5-chloropyridin-2-yl)-pyrrolidin-3(S)-yl-amino]-purin-9-yl]-tetrahydrofuran-3,4-diol, (2R,3S,4R,5R)-2-hydroxymethyl-5-[6-[1-(5-trifluoromethylpyridin-2-yl)-pyrrolidin-3(R)-ylamino]-purin-9-yl]tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-hydroxymethyl-5-[6-[1-(5-trifluoromethylpyridin-2-yl)-pyrrolidin-3(S)-ylamino]-purin-9-yl]tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-hydroxymethyl-5-[6-[1-(4-trifluoromethylpyridin-2-yl)-pyrrolidin-3(S)-ylamino]-purin-9-yl]tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-hydroxymethyl-5-[6-[1-(5-bromopyridin-2-yl)-pyrrolidin-3(S)-ylamino]-purin-9-yl]tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-hydroxymethyl-5-[6-[1-(4-nitrophenyl)-pyrrolidin-3(S)-ylamino]-purin-9-yl]tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-hydroxymethyl-5-[6-(5'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[l,2']-bipyridinyl-3-yl)-purin-9-yl]tetrahydrofuran-3,4-diol, (2R, 3R,4S,5R)-2-hydroxymethyl-5-[6-(phenylpyrrolidin-3(S)-ylamino)-purin-9-yl]tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-hydroxymethyl-5-[6-(1-pyridin-2-ylpyrrolidin-3(S)-ylamino]-purin-9-yl]tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-hydroxymethyl-5-[6-[1-(4-chlorophenyl)-pyrrolidin-3(S)-ylamino]-purin-9-yl]tetrahydrofuran-3,4-diol, (2R ,3R,4S,5R)-2-hydroxymethyl-5-[6-[1-(5-methylpyridin-2-yl)-pyrrolidin-3(S)-ylamino]-purin-9-yl]tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-hydroxymethyl-5[6-[1-(5-thiophen-2-ylpyridin-2-yl)-pyrrolidin-3(S)-ylamino]-purin-9-yl]tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-hydroxymethyl-5-[6-[l-(5-methylmercaptopyridin-2-yl)-pyrrolidin-3(S)-ylamino]-purin-9-yl]tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-hydroxymethyl-5-[6-[1-(6-methoxypyrimidin-4-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-hydroxymethyl-5-[6-[1-(6-chloropyrimidin-4-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-hydroxymethyl-5-[6-[1-(6-chloropyridazin-3-yl)pyrrolidin-3-ylamino]-purin-9-yl]-tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-methoxymethyl-5-[6-[1-(5-trifluoromethylpyridin-2-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]tetrahydrofuran-3,4-diol, (1S,2R,3R,5R)-3-hydroxymethyl-5-[6-[1-(4-nitrophenyl)piperidin-4-yl]-purin-9-yl]cyclopentane-1,2-diol, (1S,2R,3R,5R)-3-hydroxymethyl-5-[6-((3S)-pyrrolidin-3-ylamino)-purin-9-yl]cyclopentane-1,2-diol dihydrochloride, (1S,2R,3R,5R)-3-hydroxymethyl-5-[6-[1-(4-nitrophenyl)pyrrolidin-3-ylamino]-purin-9-yl]cyclopentane-1,2-diol, (1S,2R,3R,5R)-3-hydroxymethyl-5-[6-[1-(5-trifluoromethylpyridin-2-yl)pyrrolidin-3(R)-ylamino]-purin-9-yl]cyclopentane-1,2-diol, (1S,2R,3R,5R)-3-hydroxymethyl-5-[6-((3R)-pyrrolidin-3-ylamino)-purin-9-yl]cyclopentane-1,2-diol, (1R,2S,3R,5R)-3-hydroxymethyl-5-[6-[1-(5-trifluoromethylpyridin-2-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]cyclopentane-1,2-diol, (1R,2S,3R,5R)-5-[6-[1-(5-bromopyridin-2-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]-3-hydroxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-5-[6-[1-(5-chloropyridin-2-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]-3-hydroxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-3-hydroxymethyl-5-[6-[1-(4-trifluoromethylpyridin-2-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]cyclopentane-1,2-diol, (1R,2S,3R,5R)-3-hydroxymethyl-5-[6-[1-(pyridin-2-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]cyclopentane-1,2-diol, (1 R,2S,3R,5R)-3-hydroxymethyl-5-[6-[1-(quinolin-3-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]cyclopentane-1,2-diol, (1R,2S,3R,5R)-3-hydroxymethyl-5-[6-[1-S-(4-nitrophenyl)-pyrrolidin-3(S)-ylamino]-purin-9-yl]cyclopentane-1,2-diol, (1R,2S,3R,5R)-5-[6-[1-(4,5-bis-trifluorpyridin-2-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]-3-hydroxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-3-methoxymethyl-5-[6-[1-(5-trifluoromethylpyridin-2-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]cyclopentane-1,2-diol, (1R,2S,3R,5R)-3-hydroxymethyl-5-[6-[1-(phenyl)-pyrrolidin-3(S)-ylamino]-purin-9-yl]cyclopentane-1,2-diol, 4-[3(S)-[9-(2,3-dihydroxy-4-hydroxymethylcyclopentyl)-9H-purin-6-ylamino]pyrrolidin-1-yl]benzonitrile, (1R,2S,3R,5R)-3-hydroxymethyl-5-[6-[1-(isoquinolin-1-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]cyclopentane-l,2-diol, (1R,2S,3R,5R)-5-[6-[1-(6-bromoquinolin-2-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]-3-hydroxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-5-[6-[1-(4-chlorophenyl)pyrrolidin-3(S)-ylamino]-purin-9-yl]-3-hydroxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-3-[6-[1-(3-chloro-5-trifluoromethylpyridin-2-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]-3-methoxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-5-[6-[1-(6-chloropyrimidin-4-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]-3-hydroxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-5-[6-[1-(6-chloropyrimidin-4-yl)pyrrolidin-3-(S)-ylamino]-purin-9-yl]-3-hydroxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-5-[6-[1-(6-chloropyrimidin-4-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]-3-methoxymethylcyclopentane-1,2-diol, (1R, 2S,3R,5R)-5-[6-[1-(6-chloropyridazin-3-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]-3-hydroxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-3-methoxymethyl-5-[6-[1-(6-methoxypyrimidin-4-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]cyclopentane-1,2diol, (1R,2S,3R,5R)-5-[6-[1-(6-chloropyridazin-3-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]-3-methoxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-5-(-[6-[1-(4-trifluoromethylphenyl)-pyrrolidin-3(S)-ylamino]-purin-9-yl]-3-hydroxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-5-[6-[1-(5-bromopyridin-2-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]-3-methoxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-5-[6-[1-(5-chlorpyridin-2-yl)pyrrolidin-3(S)-ylamino]-purin-9-yl]-3-methoxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-3-methoxymethyl-5-[6-[1-(4-trifluoromethylphenyl)pyrrolidin-3(S)-ylamino]-purin-9-yl]cyclopentane-1,2-diol, (1R,2S,3R,5R)-5-(-[6-[1-(4-chlorophenyl)-pyrrolidin-3(S)-ylamino]-purin-9-yl]-3-methoxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-5-[6-[1-(3-chlorophenyl)pyrrolidin-3(S)-ylamno]-purin-9-yl]-3-methoxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-5-[6-[1-(3-chlorophenyl)-pyrrolidin-3(S)-ylamino]-purin-9-yl]-3-hydroxymethylcyclopentane-1,2-diol, (1R,2S,3R,5R)-3-methoxymethyl-5-[6-[1-phenylpyrrolidin-3(S)-ylamino]-purin-9-yl]cyclopentan-1,2-diol, (1R,2S,3R,5R)-3-[6-(1-benzyl-pyrrolidin-3(S)-ylamino)purin-9-yl]-5-hydroxymethylcyclopentane-1,2-diol, or (1R,2S,3R,5R)-3-[6-(1-benzyl-pyrrolidin-3(S)-ylamino)purin-9-yl]-5-methoxymethylcyclopentane-l,2-diol; or a pharmaceutically acceptable salt thereof. 4. A compound according to Claim 1 wherein Q is CH2; K is N; T is wherein R1 is H and R2 is C1-6 alkyl; A and B are hydroxy; X is , and n + p is 3 or 4; or a pharmaceutically acceptable salt thereof. 5. A compound according to Claim 4 which comprises (1S,2R,3S,4R)-2,3-dihydroxy-4-[6-[1-(5-trifluormethylpyridin-2-yl)pyrrolidin-3-ylamino]-purin-9-yl]cyclopentanecarboxylic acid ethylamide, (S)-sec-butylamide (1S,2R,3S,4R)-2,3-dihydroxy-4-[6-[1-(5-trifluormethylpyridin-2-yl)pyrrolidin-3-ylamino]-purin-9-yl]cyclopentanecarboxylic acid, and (R)-sec-butylamide (1S,2R,3S,4R)-2,3-dihydroxy-4-[6-[1-(5-trifluormethylpyridin-2-yl)pyrrolidin-3-ylamino]-purin-9-yl]cyclopentanecarboxylic acid, and a pharmaceutically acceptable salt thereof. 6. A compound according to Claim 1 wherein Q is CH2; K is N; T is hydroxymethyl or methoxymethyl; A and B are hydroxy; X is , and n + p is 3 or 4; or a pharmaceutically acceptable salt thereof. 7. A compound according to Claim 6 which is (1S,2R,3R,5R)-3-hydroxymethyl-5-[6-[1-(4-nitrophenyl)piperidin-4-yl]-purin-9-yl]cyclopentane-1,2-diol, (1S,2R,3R,5R)-3-hydroxymethyl-5-[6-((3S)-pyrrolidin-3-ylamino)-purin-9-yl]cyclopentane-1,2-diol dihydrochloride, (1S,2R,3R,5R)-3-hydroxymethyl-5-[6-[1-(4-nitrophenyl)pyrrolidin-3-ylamino]-purin-9-yl]cyclopentane-1,2-diol, (1S,2R, 3R,5R)-3-hydroxymethyl-5-[6-[l-(5-trifluoromethylpyridin-2-yl)pyrrolidin-3(R)-ylamino]-purin-9-yl]cyclopentane-1,2-diol, (1S,2R,3R,5R)-3-hydroxymethyl-5-[6-((3R)-pyrrolidin-3-ylamino)-purin-9-yl]cyclopentane-1,2-diol, (1R,2S,3R,5R)-3-hydroxymethyl-5-[6
机译:1.下式的化合物,其中:K-N,N-> O或CH; Q-CH2或O; R6是氢,C1-10烷基,烯丙基,2-甲基烯丙基,2-丁烯基或C3-10环烷基; X是X的环的氮被Y取代的位置; E是O或S; Y是氢,被苯基取代的C 1-20烷基,C 1-20烷基,被萘基取代的C 1-20烷基,被取代的苯基取代的C 1-20烷基,被取代的萘基取代的C 1-20烷基,4-10元杂环,包括至少一个原子N,O或S,被取代的4-10元杂环,包括至少一个原子N,O,S,C1-20烷基,被取代为至少一个原子N,O或S,C 1-20烷基,被取代为至少一个原子N,O ,S或C 1-20烷基,被取代的4-10元杂环取代,包含至少一个原子N,O,S; n和p独立为0、1、2或3,前提是n + p至少为1; T是氢,C 1-20烷基,C 1-20酰基,C 1-20硫酰基,卤素,羧基或R 3 O-CH 2; R 1,R 2和R 3独立地为H,C 1-20烷基,C 3-10环烷基; A为氢,C 1-20烷基,C 1-20羟烷基,C 1-20烷基,取代的C 1-20烷氧基OR'; B为氢,C1-20烷基,C1-20羟烷基,C1-20烷基,取代的C1-20烷氧基或OR''; R'和R''独立地是氢,C1-20烷基,被苯基取代的C1-20烷基,被萘基,氨基甲酰基,C1-20烷基氨基甲酰基,二-(C1-20烷基)-氨基甲酰基,酰基,C1-20烷氧羰基取代的C1-20烷基,苯基C1-20芳烷氧基羰基,萘基C1-20芳氧基羰基,苯氧基羰基,萘氧基羰基,或当A和B分别为OR'和OR''时,R'和R''可以一起形成H,ORc,其中Rc-氢,C1-20烷基,其中Rd和Re-独立地是氢,C1-20烷基;与它们所连接的碳原子一起可以形成C3-101,1-环烷基;或其药学上可接受的盐。 2.根据权利要求1的化合物,其中K是N;和T是羟甲基或甲氧基甲基; A和B为羟基:X为且n + p为3或4;或其药学上可接受的盐。 3.根据权利要求2的化合物,其为(2R,3R,4S,5R)-2-羟甲基-5- [6- [1-(5-氯吡啶-2-基)-吡咯烷-3-(S)-基] -氨基]-嘌呤-9-基]-四氢呋喃-3,4-二醇,(2R,3S,4R,5R)-2-羟甲基-5- [6- [1-(5-三氟甲基吡啶-2-基) -吡咯烷-3(R)-氨基氨基-嘌呤-9-基]四氢呋喃-3,4-二醇,(2R,3R,4S,5R)-2-羟甲基-5- [6- [1-(5-三氟甲基吡啶-2-基)-吡咯烷-3(S)-基氨基]-嘌呤-9-基]四氢呋喃-3,4-二醇,(2R,3R,4S,5R)-2-羟甲基-5- [6- [1-(4-三氟甲基吡啶-2-基)-吡咯烷-3(S)-氨基]嘌呤-9-基]四氢呋喃-3,4-二醇,(2R,3R,4S,5R)-2-羟甲基-5- [6- [1-(5-溴吡啶-2-基)-吡咯烷-3(S)-基氨基]-嘌呤-9-基]四氢呋喃-3,4-二醇,(2R,3R,4S, 5R)-2-羟甲基-5- [6- [1-(4-硝基苯基)-吡咯烷-3(S)-氨基]-嘌呤-9-基]四氢呋喃-3,4-二醇,(2R,3R, 4S,5R)-2-羟甲基-5- [6-(5'-三氟甲基-3,4,5,6-四氢-2H- [1,2']-联吡啶基-3-基)-嘌呤-9- yl] tetrahydrofuran-3,4-diol,(2R,3R,4S,5R)-2-hydroxymethyl-5- [6-(phenylpyrrolidin-3(S)) -ylamino)-purin-9-yl] tetrahydrofuran-3,4-diol,(2R,3R,4S,5R)-2-hydroxymethyl-5- [6-(1-pyridin-2-ylpyrrolidin-3(S)) -ylamino] -purin-9-yl] tetrahydrofuran-3,4-diol,(2R,3R,4S,5R)-2-hydroxymethyl-5- [6- [1-(4-chlorophenyl)-pyrrolidin-3( S)-基氨基]-嘌呤-9-基]四氢呋喃-3,4-二醇,(2R,3R,4S,5R)-2-羟甲基-5- [6- [1-(5-甲基吡啶-2-基)-吡咯烷酮-3(S)-基氨基]-嘌呤-9-基]四氢呋喃-3,4-二醇,(2R,3R,4S,5R)-2-羟甲基-5 [6- [1-(5-噻吩-2-基吡啶-2-基)-吡咯烷-3(S)-基氨基]-嘌呤-9-基]四氢呋喃-3,4-二醇,(2R,3R,4S,5R)-2-羟甲基-5 -[[6- [1-(5-甲基巯基吡啶-2-基)-吡咯烷-3(S)-氨基]-嘌呤-9-基]四氢呋喃-3,4-二醇,(2R,3R,4S,5R) -2-羟甲基-5- [6- [1-(1-(6-甲氧嘧啶-4-基)吡咯烷酮-3(S)-氨基]-嘌呤-9-基]四氢呋喃-3,4-二醇,(2R,3R ,4S,5R)-2-羟甲基-5- [6- [1-(6-氯嘧啶-4-基)吡咯烷酮-3(S)-基氨基]-嘌呤-9-基]四氢呋喃-3,4-二醇,(2R,3R,4S,5R)-2-羟甲基-5- [6- [1-(6-氯哒嗪-3-基)吡咯烷-3-基氨基]-嘌呤9 -基]-四氢呋喃-3,4-二醇,(2R,3R,4S,5R)-2-甲氧基甲基-5- [6- [1-(5-三氟甲基吡啶-2-基)吡咯烷酮-3(S)-氨基]-嘌呤-9-基]四氢呋喃-3,4-二醇,(1S,2R,3R,5R)-3-羟甲基-5- [6- [1-(4-硝基苯基)哌啶-4-基] -嘌呤-9-基]环戊烷-1,2-二醇,(1S,2R,3R,5R)-3-羟甲基-5- [6-((3S)-吡咯烷-3-基氨基)-嘌呤-9- yl]环戊烷-1,2-二醇二盐酸盐,(1S,2R,3R,5R)-3-羟甲基-5- [6- [1-(4-(硝基硝基))吡咯烷-3-基氨基]-嘌呤-9-基]环戊烷-1,2-二醇,(1S,2R,3R,5R)-3-羟甲基-5- [6- [1-(5-三氟甲基吡啶-2-基)吡咯烷-3-(R)-基氨基]-嘌呤-9-基]环戊烷-1,2-二醇,(1S,2R,3R,5R)-3-羟甲基-5- [6-(((3R)-吡咯烷-3-基氨基)]-嘌呤-9-基]环戊烷-1,2-二醇,(1R,2S,3R,5R)-3-羟甲基-5- [6- [1-(5-三氟甲基吡啶-2-基)吡咯烷烃-3(S)-氨基基氨基]-嘌呤-9-基]环戊烷-1,2-二醇,(1R,2S,3R,5R)-5- [6- [1-(5-溴吡啶-2-基)吡咯烷烃-3(S)-基氨基]-嘌呤-9-基] -3-羟甲基环戊烷-1,2-二醇,(1R ,2S,3R,5R)-5- [6- [1-(5-氯吡啶-2-基)-吡咯烷酮-3(S)-基氨基]-嘌呤-9-基] -3-羟甲基环戊烷-1,2-二醇,(1R,2S,3R,5R)-3-羟甲基-5- [6- [1-(4-三氟甲基吡啶-2-基)吡咯烷醇-3(S)-氨基氨基]-嘌呤-9-基]环戊烷-1,2-二醇,(1R,2S,3R,5R)-3-羟甲基-5- [6- [1-(吡啶-2-基)吡咯烷烃-3(S)-氨基)嘌呤-9- yl] cyclopentane-1,2-diol,(1 R,2S,3R,5R)-3-hydroxymethyl-5- [6- [1-(quinolin-3-yl)pyrrolidin-3(S)-ylamino]-嘌呤-9-基]环戊烷-1,2-二醇,(1R,2S,3R,5R)-3-羟甲基-5- [6- [1-S-(4-硝基苯基)-吡咯烷-3(S) -基氨基]-嘌呤-9-基]环戊烷-1,2-二醇,(1R,2S,3R,5R)-5- [6- [1-(4,5-双-三氟吡啶-2-基)吡咯烷酮-3(S)-基氨基]-嘌呤-9-基] -3-羟甲基环戊烷-1,2-二醇,(1R,2S,3R,5R)-3-甲氧基甲基-5- [6- [1-(5 -三氟甲基吡啶-2-基]吡咯烷-3-(S)-氨基基氨基]-嘌呤-9-基]环戊烷-1,2-二醇,(1R,2S,3R,5R)-3-羟甲基-5- [6- [1-(苯基)-吡咯rolidin-3(S)-基氨基]-嘌呤-9-基]环戊烷-1,2-二醇,4- [3(S)-[9-(2,3-二羟基-4-羟甲基环戊基)-9H-嘌呤-6-基氨基]吡咯烷-1-基]苄腈,(1R,2S,3R,5R)-3-羟甲基-5- [6- [1-(异喹啉-1-基)吡咯烷-3(S)-氨基] ]-嘌呤-9-基]环戊烷-1,2-二醇,(1R,2S,3R,5R)-5- [6- [1-(6-溴喹啉-2-基)吡咯烷酮-3(S)- ylamino] -purin-9-yl] -3-hydroxymethylcyclopentane-1,2-diol,(1R,2S,3R,5R)-5- [6- [1-(4-chlorophenyl)pyrrolidin-3(S)- [氨基]-嘌呤-9-基] -3-羟甲基环戊烷-1,2-二醇,(1R,2S,3R,5R)-3- [6- [1-(3-氯-5-三氟甲基吡啶-2-基] )吡咯烷-3-(S)-氨基氨基-嘌呤-9-基] -3-甲氧基甲基环戊烷-1,2-二醇,(1R,2S,3R,5R)-5- [6- [1-(6-氯嘧啶) -4-基)吡咯烷烃-3(S)-基氨基]-嘌呤-9-基] -3-羟甲基环戊烷-1,2-二醇,(1R,2S,3R,5R)-5- [6- [1- (6-氯嘧啶-4-基)吡咯烷-3-(S)-基氨基]-嘌呤-9-基] -3-羟甲基环戊烷-1,2-二醇,(1R,2S,3R,5R)-5- [ 6- [1-(6-氯嘧啶-4-基)吡咯烷-3(S)-氨基氨基]-嘌呤-9-基] -3-甲氧基甲基环戊烷-1,2 -二醇,(1R,2S,3R,5R)-5- [6- [1-(6-氯哒嗪-3-基)吡咯烷酮-3(S)-氨基氨基]-嘌呤-9-基] -3-羟甲基环戊烷-1,2-二醇,(1R,2S,3R,5R)-3-甲氧基甲基-5- [6- [1-(6-甲氧基嘧啶-4-基)吡咯烷蛋白-3(S)-氨基]嘌呤- 9-基]环戊烷-1,2二醇,(1R,2S,3R,5R)-5- [6- [1-(6-氯哒嗪-3-基)吡咯烷醇3(S)-基氨基]-嘌呤-9 -基] -3-甲氧基甲基环戊烷-1,2-二醇,(1R,2S,3R,5R)-5-(-[6- [1-(4-(三氟甲基苯基))-吡咯烷-3(S)-基氨基]-嘌呤-9-基] -3-羟甲基环戊烷-1,2-二醇,(1R,2S,3R,5R)-5- [6- [1-(5-溴吡啶-2--2-基)吡咯烷-3(S) -基氨基]-嘌呤-9-基] -3-甲氧基甲基环戊烷-1,2-二醇,(1R,2S,3R,5R)-5- [6- [1-(5-氯吡啶-2-基)吡咯烷酮- 3(S)-基氨基]-嘌呤-9-基] -3-甲氧基甲基环戊烷-1,2-二醇,(1R,2S,3R,5R)-3-甲氧基甲基-5- [6- [1-(4-三氟甲基苯基)吡咯烷酮-3(S)-氨基基-嘌呤-9-基]环戊烷-1,2-二醇,(1R,2S,3R,5R)-5-(-[6- [1-(4-氯苯基) )-吡咯烷酮-3(S)-基氨基]嘌呤-9-基] -3-甲氧基甲基环戊烷-1,2-二醇,(1R,2S,3R,5R)-5- [6- [1-(3-氯邻苯基)吡咯烷基3(S)-亚氨基]-嘌呤-9-基] -3-甲氧基甲基环戊烷-1,2-二醇,(1R,2S,3R,5R)-5- [6- [1-(3-氯苯基)-吡咯烷酮-3(S)-基氨基]-嘌呤-9-基] -3-羟甲基环戊烷-1,2-二醇,(1R,2S,3R,5R)-3-甲氧基甲基-5- [6- [ 1-苯基吡咯烷-3(S)-基氨基]-嘌呤-9-基]环戊烷-1,2-二醇,(1R,2S,3R,5R)-3- [6-(1-苄基吡咯丁-3( S)-基氨基)嘌呤-9-基] -5-羟甲基环戊烷-1,2-二醇,或(1R,2S,3R,5R)-3- [6-(1-苄基吡咯烷-3(S)- (氨基)嘌呤-9-基] -5-甲氧基甲基环戊烷-1,2-二醇;或其药学上可接受的盐。 4,根据权利要求1的化合物,其中Q是CH2; K是N; T是其中R 1是H且R 2是C 1-6烷基的T; A和B是羟基; X是,n + p是3或4;或其药学上可接受的盐。 5.根据权利要求4的化合物,其包含(1S,2R,3S,4R)-2,3-二羟基-4- [6- [1-(1-(5-三氟甲基吡啶-2-基)吡咯烷基-3-基氨基]-嘌呤-9-基]环戊烷羧酸乙基酰胺,(S)-仲丁基酰胺(1S,2R,3S,4R)-2,3-二羟基-4- [6- [1-(5-三氟甲基吡啶-2-基)吡咯烷-3-基氨基]-嘌呤-9-基]环戊烷羧酸和(R)-仲丁酰胺(1S,2R,3S,4R)-2,3-二羟基-4- [6- [1-(5 -三氟甲基吡啶-2-基)吡咯烷-3-基氨基]-嘌呤-9-基]环戊烷羧酸及其药学上可接受的盐。 6,根据权利要求1的化合物,其中Q是CH 2。 K是N; T是羟甲基或甲氧基甲基; A和B是羟基; X是,n + p是3或4;或其药学上可接受的盐。 7.根据权利要求6的化合物,其为(1S,2R,3R,5R)-3-羟甲基-5- [6- [1-(4-硝基苯基)哌啶-4-基]-嘌呤-9-基]。环戊烷-1,2-二醇,(1S,2R,3R,5R)-3-羟甲基-5- [6-((3S)-吡咯烷-3-基氨基)-嘌呤-9-基]环戊烷-1,2 -二盐酸二醇,(1S,2R,3R,5R)-3-羟甲基-5- [6- [1-(4-硝基苯基)吡咯烷-3-基氨基]-嘌呤-9-基]环戊烷-1,2-二醇,(1S,2R,3R,5R)-3-羟甲基-5- [6- [1-(5-三氟甲基吡啶-2-基)吡咯烷烃-3(R)-基氨基]-嘌呤-9-基]环戊烷-1,2-二醇,(1S,2R,3R,5R)-3-羟甲基-5- [6-(((3R)-吡咯烷基-3-基氨基)-嘌呤-9-基]环戊烷-1,2-二醇,(1R,2S,3R,5R)-3 -羟甲基-5- [6

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号